Researchers in Germany have identified a SOX9-responsive regulatory route to IRF6, a major orofacial-cleft risk gene, in ...
Sofi-cel is an allogeneic, off-the-shelf, CD7-targeted CAR-T cell therapy being developed for T-cell cancers. Allotera uses ...
The landscape and trajectory of global CRISPR therapeutics. This review maps the global CRISPR therapeutic landscape through a systematic analysis of CRISPR-based trials on ClinicalTrials.gov and the ...
A mutation-agnostic CRISPR-Cas strategy that inserts a functional rhodopsin coding sequence into the human RHO locus has ...
Base editing offers far more versatility than its name implies. The technique was initially developed to correct ...
CMN founder Jens-Ole Bock will moderate a panel discussion at CSGCT 2026 in Beijing on 20 September on the question that now defines the field: with the first in vivo CRISPR therapy under FDA priority ...
On 28 January 2026, nChroma Bio dosed the first participant in its Phase 1/2 clinical trial of CRMA-1001, an investigational CRISPR-Cas-based epigenetic silencer targeting chronic hepatitis B virus ...
The team behind Ariya Bio, from left to right: Mierelle Schuijt (Research Associate), Aniruddhan Balakrishnan (Corporate Strategy Intern), Mandy Boontanrart (Cofounder), Maike Getwan (Research Intern) ...
Researchers have identified how the bacteriophage protein AcrIIA27 inhibits diverse Cas9 enzymes by binding solvent-exposed regions of the guide RNA rather than the protein itself. This structural ...
Conventional CRISPR-CAS9 tools trigger immune responses in host animals, which can systematically distort screening results and mask genuine cancer vulnerabilities. A novel platform called StealTHY ...
The company’s lead candidate, AXL-003, is advancing towards preclinical evaluation in an autoimmune indication with liver-targeted delivery. This programme builds directly on results showing that AXL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results